Arailym Bopi
China National Pharmaceutical Group Corporation (China)
ORCID: 0000-0001-9480-0241Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 1 paper. Top paper: “Reassortants of the Highly Pathogenic Influenza Virus A/H5N1 Causing Mass Swan Mortality in Kazakhstan from 2023 to 2024”.
Takhmina U. Argimbayeva, Nurdos A. Aubakir, Arailym Bopi, Zamira D. Omarova, Aibarys M. Melisbek +8 more